PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Feb 7 2011PharmaMar

PharmaMar SA has announced the commencement of a Phase I clinical trial with PM060184 for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced compound which has shown strong in vitro and in vivo antitumor activity and a favorable safety profile in preclinical toxicology studies. PM060184 is PharmaMar's sixth compound in clinical development.

The trials will be performed in hospitals in the U.S., and also in France and Spain. The primary endpoints of this Phase I trial are to identify the dose limiting toxicity (DLT), the maximum tolerated dose (MTD) and the recommended dose (RD) of PM060184.

Additionally, the drug's pharmacokinetic profile will be defined and a preliminary evaluation of its antitumor activity in patients will be performed.

Source:

PharmaMar

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Pioneering vaccine strategy promises to outmaneuver antimicrobial resistance
Mediterranean diet and exercise reshape gut microbiome, aiding weight loss
New model predicts kidney injury risk in cancer patients on cisplatin
Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions
Resistant starch diet proves a game changer for weight loss and diabetes control
Daily aspirin linked to higher mortality in older adults, study finds
Esketamine after childbirth cuts risk of postnatal depression by three-quarters
Cycles of a diet that mimics fasting can reduce signs of immune system aging, as well as insulin resistance and liver fat

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial